Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, has recently received a strong customer response for its second tissue service, the ExViveTM Human Kidney Tissue. Customers use Organovo’s 3D bioprinted kidney tissue to study the effects of drug exposure through toxicology panels and transporter studies. “Nephrotoxicity is a key concern in drug development and the proximal tubule is the primary site of renal toxicity,” said Dr. Caroline Lee, senior director, Ardea Biosciences, Inc. “The ExVive Human Kidney Tissue provides an ideal means to study the impact of renal transporters on the disposition of drugs because it closely resembles native human kidney proximal tubule, with its polarized renal epithelial cells and tubulointerstitial interface and in particular its native expression level of transporters enabling formation of the transport network.” Ardea Biosciences, Inc. is a wholly-owned subsidiary of AstraZeneca PLC.
“At La Jolla Pharmaceutical Company, we incorporate in vitro models to assess nephrotoxicity in the preclinical stage of drug development,” said Dr. Andrew Seacat, director, preclinical development, La Jolla Pharmaceutical Company. “Organovo has developed an in vitro human kidney tissue model that allows for study of renal toxicity, biomarker expression, and overall cellular and tissue health following compound exposure. La Jolla currently utilizes the ExVive Human Kidney Tissue model to assess the renal impact of our compounds during development.”